目前，多发性骨髓瘤(MM)仍无法治愈，其难治与复发是临床面临的主要问题。除造血干细胞移植(HSCT)、嵌合抗原受体T细胞(CAR-T)免疫疗法外，多种基于不同作用机制的新型药物及其联合应用方案不断涌现，为复发/难治性MM(RRMM)的治疗提供了新的选择。为了进一步探索RRMM的药物治疗方案，笔者拟针对近年来国内临床应用较少或者正在进行临床研究的RRMM治疗新药进行综述。“,”At present, multiple myeloma (MM) is still incurable, and relapse or refractory are the main clinical problems. In addition to hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T cell (CAR-T) immunotherapy, a variety of new drugs based on different mechanisms and their combination regimens continue to emerge, which provide a new option for the treatment of relapsed/refractory MM (RRMM). In order to further explore the drug treatment regimens for RRMM, this article reviews literatures on new drugs emerged in recent years, which were few in clinical applications or ongoing clinical studies in China.